Cabazitaxel
- TRADE NAME: Jevtana (Sanofi-Aventis)
- INDICATIONS: Hormone-refractory metastatic prostate cancer (in combination with prednisone)
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Microtubule inhibitor
- HALF-LIFE: α-, β-, and γ-half-lives of 4 minutes, 2 hours, and 95 hours, respectively
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Antineoplastics, Atazanavir, BCG Vaccine, Carbamazepine, Cardiac glycosides, Clarithromycin, Clozapine, Conivaptan, CYP3A4 inhibitors and inducers, Dasatinib, Deferasirox, Denosumab, Doxorubicin, Echinacea, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Leflunomide, Natalizumab, Nelfinavir, Phenobarbital, Phenytoin, Pimecrolimus, Rifabutin, Rifampin, Ritonavir, Saquinavir, Sipuleucel-T, St John's Wort, Tacrolimus, Telithromycin, Trastuzumab, Vaccines, Vitamin K antagonists, Voriconazole
PREGNANCY CATEGORY: D
NEUTROPENIC DEATH and SEVERE HYPERSENSITIVITY
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 08/03/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
